In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading

Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer

(2015) C. Burdelski et al.   CLINICAL CANCER RESEARCH

Genomic Predictors of Outcome in Prostate Cancer

(2015) Peter J. Boström et al.   EUROPEAN UROLOGY

Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling

(2015) Rajal B. Shah et al.   HUMAN PATHOLOGY

A multicenter study showsPTENdeletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer

(2015) Dean A. Troyer et al.   PROSTATE

PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

(2014) Prabhakar Mithal et al.   INTERNATIONAL JOURNAL OF UROLOGY

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer

(2014) Antje Krohn et al.   MODERN PATHOLOGY

Prognostic Histopathological and Molecular Markers on Prostate Cancer Needle-Biopsies: A Review

(2014) A. Marije Hoogland et al.   Biomed Research International

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer

(2013) J Cuzick et al.   BRITISH JOURNAL OF CANCER

Multi-institutional Validation of the CAPRA-S Score to Predict Disease Recurrence and Mortality After Radical Prostatectomy

(2013) Sanoj Punnen et al.   EUROPEAN UROLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade

(2012) Maisa Yoshimoto et al.   MODERN PATHOLOGY

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

(2011) T. L. Lotan et al.   CLINICAL CANCER RESEARCH

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

(2011) Maisa Yoshimoto et al.   GENES CHROMOSOMES & CANCER

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

(2010) A H M Reid et al.   BRITISH JOURNAL OF CANCER

PTENgenomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

(2009) Kanishka Sircar et al.   JOURNAL OF PATHOLOGY